Displaying drugs 1576 - 1600 of 2602 in total
Paxalisib
GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).
Investigational
Enokizumab
A humanized immunoglobulin G1k anti-interleukin-9 mAb.
Investigational
Matched Description: … A humanized immunoglobulin G1k anti-interleukin-9 mAb. …
3,6,9,12,15-PENTAOXATRICOSAN-1-OL
Experimental
DTX-101
DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.
Investigational
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
PG-530742
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Investigational
Arginine
An essential amino acid that is physiologically active in the L-form.
Investigational
Nutraceutical
Matched International brands: … R-Gene 10 …
Matched Mixtures name: … Lytensopril-90 ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 1000 ML …
Matched Mixtures name: … Lytensopril-90 ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 1000 ML …
Mirvetuximab
Investigational
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). ... clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 …
Rheinanthrone
Rheinanthrone is the active metabolite of senna glycoside DB11365 known for its laxative effect . It is commonly produced by plants of the Rheum species .
Experimental
Matched Iupac: … 4,5-dihydroxy-10-oxo-9,10-dihydroanthracene-2-carboxylic acid …
JQ1
First-in-class potent and selective inhibitor of the BRD4 signaling pathway.
Investigational
Matched Iupac: … chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- …
Denecimig
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.
Investigational
Matched Description: … Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9. …
Technetium TC-99M trofolastat
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
Tanespimycin
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
Matched Iupac: … tetramethyl-20,22-dioxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),2,4,6,10,18-hexaen-9- …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Cannabinol
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
CTX130
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational
Tavokinogene telseplasmid
Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Investigational
105AD7
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL
Experimental
Displaying drugs 1576 - 1600 of 2602 in total